The iMAP platform – Multimodal Imaging Applied to Pathology is proud to announce that it has been awarded the IBiSA label for a period of two years.
In early 2025, iMAP applied to join the IBiSA network, which supports technological platforms in their technological and methodological development projects, as well as in their quality management processes.
Following the evaluation of the scientific dossier and an on-site visit, iMAP was granted the IBiSA label, recognizing its expertise, strong commitment, and openness to the scientific community.
Bringing together researchers and pathologists within a unique environment, iMAP offers comprehensive expertise in multimodal imaging, including histology, immunohistochemistry, multiplex immunofluorescence, and mass spectrometry imaging.
The platform also provides transcriptomic and bioinformatics analyses, enabling the integration of molecular data with morphological features to better understand tissue heterogeneity, particularly in the fields of inflammation and cancer.
A well-deserved recognition for the iMAP team, the CRI – Centre de Recherche sur l’Inflammation, and all their partners Bruker @CelldiveLeica Microsystems @IBiSA @iMAP @MultimodalImaging Université Paris Cité CNRS Inserm hopital beaujon Valerie Paradis Helene Cazier Diana MENDES Jerome Cros Rémy Nicolle